YSYuqi Shen

Yuqi Shen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yuqi Shen has a total of 105 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Belantamab mafodotin triggers immune invigoration in multiple myeloma via inflammatory and immunogenic cell death

    by Edmund Cr Watson, Halima Ali Shuwa, Morgan Heycock, Jennifer Wade, Chen-Yi Wang, Mint Htun, Lingzi Li, Vivianne Niehaus, Warren Baker, Benjamin Miller, et al.

    Objective: Belantamab mafodotin, an antibody-drug conjugate targeting B-cell maturation antigen, has demonstrated significant clinical efficacy in combination therapies for relapsed/refractory multiple myeloma. Belantamab mafodotin exerts therapeutic effects through cytotoxicity of its payload, monomethyl auristatin F, and mediation of antibody-induced cell death. Long-term clinical responses were observed with monotherapy treatment, despite dose holds, suggesting adaptive immune system involvement. We aimed to explore mechanisms of belantamab mafodotin-triggered cell death and how this contributes to immune remodelling. Design: Cell lines, myeloma patient bone marrow and samples from belantamab mafodotin-treated patients were used to explore belantamab mafodotin-driven cell death and their downstream influence on the tumour microenvironment. Results: Here, we show that belantamab mafodotin induces markers of immunogenic and inflammatory cell death in vitro and ex vivo. Belantamab mafodotin monotherapy treatment triggers acute inflammation detectable in patient serum within 24 hours, with increases in granzyme B, CXCL9, CCL3 and CCL4 linked to response depth achieved. High expression of low-density lipoprotein receptor-related protein 1 (LRP1) and toll-like receptor 2 (TLR2), receptors that mediate immunogenic cell death on patients’ monocytoid (monocyte/macrophage) cells, suggests an important function of monocytoid cells to mediate the inflammation and immunogenic cell death cascades. Inflammation is followed by remodelling of the innate and adaptive immune system, a reduction in immune inhibitory signalling and the emergence of CD4 granzyme B-expressing cells in patients in remission versus those that relapse. Conclusion: Belantamab mafodotin’s ability to promote adaptive immune responses and its cytotoxic activity may help explain the durable responses observed in treated patients, despite dose and schedule modifications.


  • CAR T cell therapy selectively depletes disease-driving mutant calreticulin cells in xenotransplants and human organoid models of myelofibrosis

    by Alexandros Rampotas, Zoë C. Wong, Isaac Gannon, Charlotte K. Brierley, Yuqi Shen, Camelia Benlabiod, Ashlyn Chee, Saif Khan, Nawshad Hayder, Gordon Weng-Kit Cheung, et al.

    Targeted immunotherapies have revolutionized outcomes for lymphoid malignancies, but success in myeloid neoplasms is limited by the lack of amenable targets and immunologically hostile tumor microenvironment (TME). Myeloproliferative neoplasms (MPNs) are chronic myeloid blood cancers, a third of which are driven by mutations in calreticulin. Calreticulin mutant protein (mutCALR) binds and activates thrombopoietin receptor (TpoR) and results in the display of the mutCALR-TpoR complex on the extracellular membrane of disease-driving cells, thus exposing a therapeutic vulnerability. Here, we present a chimeric antigen receptor T cell (CAR T cell) therapy that specifically targets mutCALR+ cells, both in vitro and in vivo. The CAR T cell therapy selectively depleted mutCALR+ stem cells in samples from patients with myelofibrosis without affecting healthy stem cells and improved survival in mutCALR leukemia xenograft models. To mimic myelofibrotic marrow, we developed a human “chimeroid” model and showed no decrease in the potency of CAR T cell–mediated target cell killing even in a fibrotic TME. We also devised a method to boost the cell surface expression of mutCALR in CD34+ cells isolated from patients with accelerated/blast phase MPNs (defined as >10% blasts in the peripheral blood or bone marrow), enhancing CAR T cell targeting. This study presents a therapeutic strategy with potential to eradicate mutCALR-driven malignancies and highlights an innovative strategy to evaluate blood cancer–targeting immunotherapies in a relevant TME.


  • Open Access

    ATRX loss couples genome instability at a G-rich repeat to dysregulation of human alpha-globin expression

    by Yuqi Shen, Kinam Gupta, Sue Mei Tan-Wong, Sean Wen, Christopher A. Fisher, Liezel Tamon, Nicholas J. Proudfoot, Richard J. Gibbons, Douglas R. Higgs

    Germline mutations in the chromatin remodelling protein ATRX cause a severe developmental disorder associated with α-thalassemia. In addition, ATRX is amongst the twenty genes most frequently mutated in cancer. How ATRX mutations alter gene expression remains unclear. Using the α-globin locus as a model, here we show that ATRX deficiency downregulates α-globin in a subset of cells exhibiting DNA damage. A G-rich repeat at the α-globin locus serves as a potential site of G-quadruplex formation and DNA damage. ATRX binds this repeat co-transcriptionally, and its loss increases R-loop accumulation at this site, leading to local DNA damage and transcriptional disruption in cis . Deletion of this repeat abolishes this effect, while targeted DNA damage reinstates it. These findings reveal a mechanism linking ATRX’s role in genome stability to transcriptional regulation and uncover a molecular basis of human genetic disease mediated via a distal G-rich repeat.

  • Open Access

    Human Multi-Organoid Platform to Model Immune Dynamics in Cardiac Injury and Disease

    by Jasmeet S. Reyat, Yuqi Shen, Gowsihan Poologasundarampillai, Amirpasha Moetazedian, Julie Rayes, Abdullah O. Khan


  • Open Access

    Perturbing LSD1 and WNT rewires transcription to synergistically induce AML differentiation

    by Amir Hosseini, Abhinav Dhall, Nemo Ikonen, Natalia Sikora, Sylvain Nguyen, Yuqi Shen, Maria Luisa Jurgensen Amaral, Alan Jiao, Felice Wallner, Philipp Sergeev, et al.

    Impaired differentiation is a hallmark of myeloid malignancies1,2. Therapies that enable cells to circumvent the differentiation block, such as all-trans retinoic acid (ATRA) and arsenic trioxide (ATO), are by and large curative in acute promyelocytic leukaemia3, but whether ‘differentiation therapy’ is a generalizable therapeutic approach for acute myeloid leukaemia (AML) and beyond remains incompletely understood. Here we demonstrate that simultaneous inhibition of the histone demethylase LSD1 (LSD1i) and the WNT pathway antagonist GSK3 kinase4 (GSK3i) robustly promotes therapeutic differentiation of established AML cell lines and primary human AML cells, as well as reducing tumour burden and significantly extending survival in a patient-derived xenograft mouse model. Mechanistically, this combination promotes differentiation by activating genes in the type I interferon pathway via inducing expression of transcription factors such as IRF7 (LSD1i) and the co-activator β-catenin (GSK3i), and their selective co-occupancy at targets such as STAT1, which is necessary for combination-induced differentiation. Combination treatment also suppresses the canonical, pro-oncogenic WNT pathway and cell cycle genes. Analysis of datasets from patients with AML suggests a correlation between the combination-induced transcription signature and better prognosis, highlighting clinical potential of this strategy. Collectively, this combination strategy rewires transcriptional programs to suppress stemness and to promote differentiation, which may have important therapeutic implications for AML and WNT-driven cancers beyond AML.


  • Open Access

    Author Correction: The α-globin super-enhancer acts in an orientation-dependent manner

    by Mira T. Kassouf, Helena S. Francis, Matthew Gosden, Maria C. Suciu, Damien J. Downes, Caroline Harrold, Martin Larke, Marieke Oudelaar, Lucy Cornell, Joseph Blayney, et al.

  • Open Access

    The α-globin super-enhancer acts in an orientation-dependent manner

    by Mira T. Kassouf, Helena S. Francis, Matthew Gosden, Maria C. Suciu, Damien J. Downes, Caroline Harrold, Martin Larke, Marieke Oudelaar, Lucy Cornell, Joseph Blayney, et al.

    Individual enhancers are defined as short genomic regulatory elements, bound by transcription factors, and able to activate cell-specific gene expression at a distance, in an orientation-independent manner. Within mammalian genomes, enhancer-like elements may be found individually or within clusters referred to as locus control regions or super-enhancers (SEs). While these behave similarly to individual enhancers with respect to cell specificity, distribution and distance, their orientation-dependence has not been formally tested. Here, using the α-globin locus as a model, we show that while an individual enhancer works in an orientation-independent manner, the direction of activity of a SE changes with its orientation. When the SE is inverted within its normal chromosomal context, expression of its normal targets, the α-globin genes, is severely reduced and the normally silent genes lying upstream of the α-globin locus are upregulated. These findings add to our understanding of enhancer-promoter specificity that precisely activate transcription.